Creative Medical Technology (NASDAQ:CELZ) Shares Up 5.3% – Should You Buy?

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was up 5.3% during trading on Monday . The company traded as high as $2.23 and last traded at $2.17. Approximately 30,890 shares traded hands during trading, a decline of 39% from the average daily volume of 50,695 shares. The stock had previously closed at $2.06.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Creative Medical Technology in a research report on Friday, May 22nd. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Creative Medical Technology has an average rating of “Reduce”.

Creative Medical Technology Trading Up 5.3%

The stock has a market cap of $8.03 million, a P/E ratio of -1.01 and a beta of 1.84. The business’s fifty day simple moving average is $2.22 and its 200 day simple moving average is $2.12.

Creative Medical Technology (NASDAQ:CELZ) last announced its earnings results on Friday, May 8th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.01. On average, analysts predict that Creative Medical Technology Holdings, Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Creative Medical Technology stock. Jane Street Group LLC bought a new stake in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned about 1.17% of Creative Medical Technology at the end of the most recent quarter. Hedge funds and other institutional investors own 1.42% of the company’s stock.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.